Multicenter trial of effects for glucometabolism, platelet activation marker and inflammatory marker by single or combinathin therapy with tofogliflozin and anagliptin in type 2 diabetic patients
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000028634
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. type 1 diabetes or secondary diabetes 2. contraindication for medicine 3. allergy 4. eGFR < 30mL/min/1.73m2 5. AST or ALT > 120IU/L 6. history of appoplexy 7. pregnancy or lactationperiod 8. urinary infection, social disease 9. malignancy 10. inappropriate patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of HbA1c during 24 weeks from baseline
- Secondary Outcome Measures
Name Time Method